The effect of medical cannabis on gastrointestinal symptoms in fibromyalgia and disorders of gut-brain interaction: a patient‑centred real‑world observational study
This study supports Bedrocan® medical cannabis as an alternative treatment for FM with a potential effect on FD and IBS symptoms. Despite positive outcomes, the study acknowledges limitations, such as the small sample size and absence of a control group. Further research is required to confirm the efficacy of medical cannabis in FM patients, particularly regarding its effects on GI symptoms.
Authors
- Greta Pellegrino (ORCID: https://orcid.org/0000-0002-1762-0770)
- Paolo Moscato (ORCID: https://orcid.org/0000-0002-8980-5141)
- Anna Merchionda
- Paola Iovino (ORCID: https://orcid.org/0000-0002-9568-0680)
- Anna Lauritano (ORCID: https://orcid.org/0000-0001-6788-5999)
- Piercarlo Sarzi‐Puttini (ORCID: https://orcid.org/0000-0002-8673-5133)
- Antonella Santonicola (ORCID: https://orcid.org/0000-0001-9094-765X)
- Carlo Soldaini (ORCID: https://orcid.org/0009-0007-6969-6949)
- Gabriella Loi
- Paola D'Addieco
Institutions
- Università Cattolica del Sacro Cuore (IT)
- University of Salerno (IT)
- Istituto Clinico Sant'Ambrogio (IT)
- Ospedali Riuniti San Giovanni di Dio e Ruggi d'Aragona (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- National Research Council (IT)
Publication Details
- Journal
- Clinical and Experimental Rheumatology
- Published
- 2025-03-22
- DOI
- https://doi.org/10.55563/clinexprheumatol/o5ck22
- Citations
- 1
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 1.39